Evaluation of bovine spongiform encephalopathy risk via the use of materials of bovine origin in or during the manufacture of vaccines - Scientific guideline

This document addresses the safety of the use of bovine-origin materials in vaccines. It concludes that the risk of BSE contamination of vaccines used within the European Union is extremely low thanks to the safety measures being taken.

Keywords: Bovine spongiform encephalopathy (BSE), risk, vaccine

Current effective version

Public statement on the evaluation of bovine spongiform encephalopathies (BSE) - risk via the use of materials of bovine origin in or during the manufacture of vaccines

AdoptedReference Number: EMEA/CPMP/BWP/476/01Legal effective date: 28/02/2001